A tiny Australian biotech that experienced a very public and explosive clinical trial failure is once again in the spotlight — this time, for its ties to a US Congressman now charged on a high-profile insider trading case.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,